<DOC>
	<DOCNO>NCT01810926</DOCNO>
	<brief_summary>• The primary aim present trial ass randomize fashion benefit standard graft-versus-host disease ( GVHD ) prophylaxis addition ATG-Fresenius S ® transplant match related donor ( MRD ) anti-CD20 rituximab transplant match unrelated donor ( MUD ) . Both safety efficacy treatment assess , particular respect clinical status patient , i.e . prevention graft failure chronic GvHD Ebstein Barr virus ( EBV ) viremia MUD patient . The conditioning propose combine myeloablative drug favorable safety profile treosulfan , thiotepa ( Tepadina® ) fludarabine intent reduce traditional immediate late toxicity busulfan cyclophosphamide .</brief_summary>
	<brief_title>T &amp; B Depletion Non Malignant</brief_title>
	<detailed_description>For patient transplant MRD The primary end-point cumulative incidence combine end-point defined time randomization : - primary secondary graft failure , - aGVHD II-IV , - cGVHD , - death , whichever occur first . For patient transplant MUD The primary end-point cumulative incidence combine end-point defined time randomization : - aGVHD II-IV , - EBV viremia , whichever occur first .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>non malignant haematological inherit metabolic disorder benefit allogeneic HSCT condition myeloablative regimen Availability match related donor ( MRD ) Matched Unrelated Donor ( MUD ) Lansky Karnofsky Index ≥ 60 Inherited metabolic disorder : DQ ≥ 70 ( + MRI Loes score ≤ 9 adrenoleukodystrophy ) Adequate cardiac , renal , hepatic pulmonary function evidence : Serum creatinine ≤ 1.5 × upper limit normal ( ULN ) Heart shorten fraction ( leftventricle ) &gt; 28 % LVEF &gt; 55 % Serum bilirubin ≤ 1.5 × ULN ( except Wolman disease ) , AST ALT ≤ 2.5 × ULN ( except thalassemic syndrome Wolman disease ) Pulmonary function : cooperative : FEV1 FVC pulmonary function test &gt; 60 % ; non cooperative : pulse oximetry &gt; 95 % room air Availability autologous back marrow ( &gt; 2 x 108 TNC+ cells/kg &gt; 2 x 106 CD34+ cells/kg ) MUD Adequate contraception female patient childbearing potential Signed inform consent Any malignancy Liver cirrhosis evidence liver histology ( perform suspicious case case Wolman disease ) HIV positivity Clinically significant pleural effusion ascites Pregnancy lactation Known hypersensitivity trial drug Participation another experimental drug trial 2 month precede enrollment Noncooperative behaviour noncompliance Previous HSCT</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>indication HSCT</keyword>
	<keyword>match related donor</keyword>
	<keyword>MRD</keyword>
	<keyword>Matched Unrelated Donor</keyword>
	<keyword>MUD</keyword>
</DOC>